William Pao
Departments of Medicine
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York
USA
Name/email consistency: high
- Defining clinically relevant molecular subsets of lung cancer. Pao, W. Cancer Chemother. Pharmacol. (2006)
- KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., Kris, M.G., Varmus, H.E. PLoS Med. (2005)
- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., Varmus, H. PLoS Med. (2005)
- Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. Pao, W., Miller, V.A. J. Clin. Oncol. (2005)
- 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Pao, W., Miller, V.A., Kris, M.G. Semin. Cancer Biol. (2004)
- EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H. Proc. Natl. Acad. Sci. U.S.A. (2004)
- Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance. Pao, W., Klimstra, D.S., Fisher, G.H., Varmus, H.E. Proc. Natl. Acad. Sci. U.S.A. (2003)
